Caricamento...
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...
Salvato in:
| Pubblicato in: | Ann Clin Microbiol Antimicrob |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://ncbi.nlm.nih.gov/pubmed/26054754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-015-0090-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|